famotidine has been researched along with Scleroderma, Systemic in 2 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horikoshi, T | 2 |
| Matsuzaki, T | 2 |
| Sekiguchi, T | 2 |
| Kusano, M | 1 |
2 trials available for famotidine and Scleroderma, Systemic
| Article | Year |
|---|---|
Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis.
Topics: Cimetidine; Esophagogastric Junction; Famotidine; Female; Gastrointestinal Motility; Humans; Injecti | 1994 |
Effects of famotidine on upper gastrointestinal motility in patients with progressive systemic sclerosis.
Topics: Adult; Bicarbonates; Chi-Square Distribution; Famotidine; Female; Gastrins; Gastrointestinal Motilit | 1991 |